Norvasc and Abraxane drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Norvasc (amlodipine besylate) and Abraxane (paclitaxel). Common drug interactions include foot deformity among females and anaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Norvasc and Abraxane. It is created by eHealthMe based on reports of 97 people who take the same drugs from the FDA, and is updated regularly.

What is Norvasc?

Norvasc has active ingredients of amlodipine besylate. It is often used in high blood pressure. eHealthMe is studying from 136,738 Norvasc users. Check the latest studies of Norvasc.

What is Abraxane?

Abraxane has active ingredients of paclitaxel. It is often used in breast cancer metastatic. eHealthMe is studying from 19,196 Abraxane users. Check the latest studies of Abraxane.

On Aug, 02, 2026

97 people who take Norvasc and Abraxane together, and have interactions are studied.

What are the common drug interactions of Norvasc and Abraxane, by gender? *:

female:

Foot deformity (functional disability of foot)
Foot fracture
Gait disturbance
Gingival erosion (gum ulcer)
Herpes zoster
Ischaemia (insufficient supply of blood to an organ, usually due to a blocked artery)
Loss of consciousness
Mass
Meniscus lesion (lesion of a crescent-shaped piece of cartilage between the femur and the tibia)
Neck pain

male:

Anaemia (lack of blood)
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
White blood cell count decreased
Febrile neutropenia (fever with reduced white blood cells)
Neutropenia (an abnormally low number of neutrophils)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Fall
Fungal infection
Hiccups (an involuntary spasm of the diaphragm and respiratory organs, with a sudden closure of the glottis and a sound like a cough)
Injury

What are the common drug interactions of Norvasc and Abraxane, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Thrombotic microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury)

40-49:

Asthenia (weakness)
Burning sensation
Dyspnoea (difficult or laboured respiration)
Fatigue (feeling of tiredness)
Flushing (the warm, red condition of human skin)
Heart rate increased
Oropharyngeal pain
Sinusitis (inflammation of sinus)
Tumour marker increased

50-59:

Neuropathy peripheral (surface nerve damage)
Tumour associated fever (fever because of tumour)
Abdominal distension
Blood alkaline phosphatase increased
Chest pain
Constipation
Dehydration (dryness resulting from the removal of water)
Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
Dyspepsia (indigestion)
Dyspnoea (difficult or laboured respiration)

60+:

Neutropenia (an abnormally low number of neutrophils)
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Anxiety
Asthenia (weakness)
Death
Delirium (wild excitement)
Drug eruption (adverse drug reaction of the skin)
Cardiac failure
Dyspnoea (difficult or laboured respiration)
Embolism (obstruction of an artery, typically by a clot of blood or an air bubble)

What are the existing conditions these people have? *

Pancreatic Carcinoma Metastatic (pancreatic cancer- metastatic): 16 people, 16.49%
Pancreatic Carcinoma (pancreatic cancer): 12 people, 12.37%
Nausea (feeling of having an urge to vomit): 12 people, 12.37%
Pain: 10 people, 10.31%
Lung Cancer - Non-Small Cell (lung cancer): 9 people, 9.28%
Adenocarcinoma Pancreas (cancer of pancreas): 7 people, 7.22%
Insomnia (sleeplessness): 6 people, 6.19%
Diarrhea: 6 people, 6.19%
Breast Cancer: 6 people, 6.19%

* Approximation only. Some reports may have incomplete information.

Do you take Norvasc and Abraxane?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously